Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136428 | 1.00 | ECE1 (0.45) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL8500636 | 1.00 | ECE1 (0.45) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL8397119 | 1.00 | ECE1 (0.45) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL6129700 | 1.00 | ECE1 (0.45) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL1487366 | 0.99 | ECE1 (0.46) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL8717802 | 0.97 | ECE1 (0.43) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL9228819 | 0.97 | ECE1 (0.43) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL29592041 | 0.97 | ECE1 (0.43) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL8717771 | 0.97 | ECE1 (0.43) | ECE1PTGS1GSTK1MEN1KMT2A | |
| SCHEMBL7464934 | 0.97 | ECE1 (0.43) | ECE1PTGS1GSTK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111471719-B | Efficient non-meiotic allele introgression | 重组股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117098526-A | Clostridium neurotoxin comprising exogenous activating ring | 益普生生物制药有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-115698268-A | Transposition-based therapies | 萨利欧基因治疗公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113573727-A | New use of botulinum neurotoxin for the treatment of tremors | 梅尔兹制药公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-110938150-B | Preparation method and application of E-type botulinum toxin recombinant L-HN antigen | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA China (CN) | 2021-08-31 | — | — | CN | disclosed |
| CN-107207586-B | Device and method for determining biological activity of BoNT/E in cells | 莫茨药物股份两合公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-112351992-A | Botulinum toxin cell binding domain polypeptides and methods for their use in skin regeneration | 阿勒根公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-112351991-A | Botulinum toxin cell binding domain polypeptides and methods for their use in treating fibrosis related disorders | 阿勒根公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-111647627-A | Multiple gene editing | 重组股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111471719-A | Efficient non-meiotic allele introgression | 重组股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-101903035-A | Methods of treating chronic neurogenic inflammation using modified clostridial toxins | ALLERGAN INC | 2010-12-01 | — | — | CN | disclosed |
| CN-101732717-A | Ttk in diagnosis and as a therapeutic target in cancer | NOVARTIS VACCINES & DIAGNOSTIC | 2010-06-16 | — | — | CN | disclosed |
| CN-100578227-C | TTK for diagnosis and as a therapeutic target for cancer | CHIRON CORP | 2010-01-06 | — | — | CN | disclosed |
| CN-100390283-C | i(Chlanydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection | GENSET SA (FR) | 2008-05-28 | — | — | CN | disclosed |
| CN-101107361-A | Recombinant expression of disulfide-bridged, double-stranded forms of proteins | BIOTECON THERAPEUTICS GMBH (DE) | 2008-01-16 | — | — | CN | disclosed |
| EP-1105153-A4 | MULTIVALENT VACCINE FOR (CLOSTRIDIUM BOTULINUM) NEUROTOXIN | OPHIDIAN PHARM INC (US) | 2005-01-19 | — | — | EP | disclosed |
| CN-1492875-A | TTK for diagnosis and as a therapeutic target for cancer | ϣ | 2004-04-28 | — | — | CN | disclosed |
| EP-1105153-A1 | MULTIVALENT VACCINE FOR (CLOSTRIDIUM BOTULINUM) NEUROTOXIN | OPHIDIAN PHARMACEUTICALS, INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| CN-1279717-A | Genomic sequence of Chlamydia pneumoniae and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infections | GENSET SA (FR) | 2001-01-10 | — | — | CN | disclosed |
| WO-1998008540-A1 | MULTIVALENT VACCINE FOR CLOSTRIDIUM BOTULINUM NEUROTOXIN | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1998-03-05 | — | — | WO | disclosed |